Rebecca Stanbrook is the Founder and Director of RESaltas GmbH, a specialist GCP and pharmacovigilance consultancy based in Muttenz, near Basel. She has worked in the pharmaceutical sector for over thirty years, as a regulator and in industry.
She spent eleven years at the MHRA, latterly as Group Manager for the GCP, Pharmacovigilance and GLP Inspectorates, where she was closely involved in establishing the UK risk-based statutory inspection programmes. Her teams at the MHRA wrote the Good Clinical Practice Guide and the Good Pharmacovigilance Practice Guide. She then spent twelve years at Novartis, in a variety of roles, latterly as GCP Strategic Lead in the Process, Risk and Surveillance team.
Rebecca is a member of the ICH Expert Working Group that authored ICH E6(R3), serving as EFPIA Topic Lead. She is a pharmacist by profession and holds a Diploma in Research Quality Assurance.
Through RESaltas she delivers mock inspections, GCP and pharmacovigilance training, and regulatory strategy support.
